Inxight Drugs

U.S. Department of Health & Human Services Divider Arrow

National Institutes of Health Divider Arrow

NCATS

Return Home Inxight Drugs

Home
Browse Drugs
Search
- Structure Search
- Sequence Search
Downloads
About

Show Filters

Hide Filters

Development Status

Possibly Marketed Outside US

1

US Approved OTC

1

US Approved Rx

1

All Match

Any Match

Exclude Selected

Exclude Selected

Primary Target

Adrenergic receptor

1

DNA

1

Dopamine D4 receptor

1

All Match

Any Match

Exclude Selected

Exclude Selected

Highest Phase

Approved

2

All Match

Any Match

Exclude Selected

Exclude Selected

Approval Year

1901

1

1978

1

Unknown

1

All Match

Any Match

Exclude Selected

Exclude Selected

Condition

Advanced bladder cancer

1

Anaphylaxis

1

Metastatic ovarian tumors

1

Metastatic testicular tumors

1

Miosis

1

All Match

Any Match

Exclude Selected

Exclude Selected

Treatment Modality

Primary

2

Preventing

1

All Match

Any Match

Exclude Selected

Exclude Selected

CNS Activity

CNS Active

1

CNS Non-penetrant

1

All Match

Any Match

Exclude Selected

Exclude Selected

Originator

Abel, J.|Takamine, J.

1

Peyrone, M.

1

All Match

Any Match

Exclude Selected

Exclude Selected

Substance Class

Chemical

2

Protein

1

All Match

Any Match

Exclude Selected

Exclude Selected

Code System

CAS

3

ChEMBL

3

DRUG BANK

3

EVMPD

3

FDA ORPHAN DRUG

3

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 1

ALIMENTARY TRACT AND METABOLISM

1

ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS

1

BLOOD AND BLOOD FORMING ORGANS

1

CARDIOVASCULAR SYSTEM

1

RESPIRATORY SYSTEM

1

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 2

ANTIHEMORRHAGICS

1

ANTINEOPLASTIC AGENTS

1

CARDIAC THERAPY

1

DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES

1

NASAL PREPARATIONS

1

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 3

ADRENERGICS, INHALANTS

1

ANTIGLAUCOMA PREPARATIONS AND MIOTICS

1

CARDIAC STIMULANTS EXCL. CARDIAC GLYCOSIDES

1

DECONGESTANTS AND OTHER NASAL PREPARATIONS FOR TOPICAL USE

1

OTHER ANTINEOPLASTIC AGENTS

1

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 4

Adrenergic and dopaminergic agents

1

Adrenergics in combination with corticosteroids or other drugs, excl. anticholinergics

1

Alpha- and beta-adrenoreceptor agonists

1

Local hemostatics

1

Other agents for local oral treatment

1

All Match

Any Match

Exclude Selected

Exclude Selected

Substance Form

Principal Form

2

Salts, Hydrates, Esters, etc.

1

All Match

Any Match

Exclude Selected

Exclude Selected

Search results for "ORPHAN DRUG|Designated|Treatment of metastatic malignant melanoma." in comments (approximate match)

Showing 1 - 3 of 3 results

First page disabled
Previous page disabled
1
Next page disabled
Next page disabled

CISPLATIN

Q20Q21Q62J

Export Data
Search for Structure

Status:

US Approved Rx (1978)

First approved in 1978

Class (Stereo):

CHEMICAL (ACHIRAL)

Targets:

Conditions:

Advanced bladder cancer

Metastatic ovarian tumors

Metastatic testicular tumors

Non-small cell lung cancer

There is no available sources on the medical use of platinum iodide. The salt is insoluble.

TECELEUKIN

H5ZRB188EI

Subunit 1 (134) Similarity Search

Export Data
Sequence Search

Subunit 1 (134) Similarity Search

Status:

Possibly Marketed Outside US

Class:

PROTEIN

EPINEPHRINE

YKH834O4BH

Export Data
Search for Structure

Status:

US Approved OTC

First marketed in 1901

Class (Stereo):

CHEMICAL (ABSOLUTE)

Targets:

Dopamine D4 receptor

Adrenergic receptor

Conditions:

Epinephrine is a sympathomimetic catecholamine. It acts as a naturally occurring agonist at both alpha and beta-adrenergic receptors. Three pharmacologic types have been identified: alpha 1-, alpha 2-, and beta-adrenergic receptors. Each of these has...

three subtypes, characterized by both structural and functional differences. The alpha 2 and beta receptors are coupled negatively and positively, respectively, to adenylyl cyclase via Gi or Gs regulatory proteins, and the alpha 1 receptors modulate phospholipase C via the Go protein. Subtype expression is regulated at the level of the gene, the mRNA, and the protein through various transcriptional and postsynthetic mechanisms. Through its action on alpha-adrenergic receptors, epinephrine lessens the vasodilation and increased vascular permeability that occurs during anaphylaxis, which can lead to loss of intravascular fluid volume and hypotension. Through its action on beta-adrenergic receptors, epinephrine causes bronchial smooth muscle relaxation and helps alleviate bronchospasm, wheezing and dyspnea that may occur during anaphylaxis. Epinephrine also alleviates pruritus, urticaria, and angioedema and may relieve gastrointestinal and genitourinary symptoms associated with anaphylaxis because of its relaxer effects on the smooth muscle of the stomach, intestine, uterus and urinary bladder. Epinephrine increases glycogenolysis, reduces glucose up take by tissues, and inhibits insulin release in the pancreas, resulting in hyperglycemia and increased blood lactic acid.

HHS VULNERABILITY DISCLOSURE

For language access assistance, contact the NCATS Public Information Officer

National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966


			version 1.1